, /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, announced today that it will report its financial results for the second quarter 2026 ended June 28, 2026, after the market closes on Thursday, August 6, 2026.
Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho.com. Presentation materials will also be posted to the "Events & Presentations" section of the "Investor Relations" page of the Company's website at the time of the call. A replay of the conference call will be available shortly after the event on the "Investor Relations" page of the Company's website under the "Events & Presentations" section.
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Key Takeaways QuidelOrtho is poised for growth on its strong product portfolio and cost-saving progress.QDEL's Labs business leads first-quarter revenues, with Immunohematology and Point of Care adding support.Respiratory testing remains a key swing factor as lower demand pressures revenues and margins. QuidelOrtho Corporation (QDEL - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by mixed first-quarter 2026 results, is expected to contribute further, along with progress in cost-saving initiatives. However, risks due to overdependence on the respiratory business persist.
This Zacks Rank #2 (Buy) company has lost 41.6% in the year-to-date period compared with the 21.8% decline of the industry. The S&P 500 has witnessed 9.5% growth in the said time frame.
The renowned rapid diagnostic testing solutions provider has a market capitalization of $1.12 billion. QuidelOrtho’s earnings yield of 11.4% compares favorably with the industry’s 3.1%. The company surpassed the Zacks Consensus Estimate in two of the trailing four quarters, missed once and met estimates once, delivering an average negative surprise of 15.7%.
Image Source: Zacks Investment Research
Factors Favoring QDEL’s GrowthRobust Product Portfolio: QuidelOrtho’s diversified portfolio across Labs, Immunohematology, Point of Care and Molecular Diagnostics helps cushion demand fluctuations across testing categories. In the first quarter of 2026, Labs remained the largest revenue contributor at $353.1 million, followed by Immunohematology at $138.3 million and Point of Care at $112.8 million.
The company's Sofia platform and QuickVue franchise continue to provide scale in respiratory testing, with management noting stable market share during the quarter. For 2026, QuidelOrtho expects a typical flu season and stable testing protocols, with guidance based on a 50-55 million annual flu testing market and flat COVID-related revenues compared with 2025.
Growth initiatives remain focused on menu expansion and international penetration, with the U.S. launch of its high-sensitivity troponin assay already reaching more than 300 customer shipments and the rollout of the VITROS 450 system targeting lower-volume laboratories, which management believes can drive mid-single-digit long-term growth in the Labs business.
Progress on Cost-Saving Initiatives: QuidelOrtho is leveraging restructuring and productivity initiatives to expand margins and support investments in new platforms. In first-quarter 2026, adjusted operating expenses declined 2% year over year, led by a 19% reduction in R&D spending, while management reaffirmed its full-year adjusted EBITDA margin target of approximately 23%.
Through its Optimization Plan, the company is pursuing procurement efficiencies, facility consolidation and distribution rationalization, expecting around $50 million in net cost savings through 2027 despite cumulative pre-tax charges of about $100 million. QuidelOrtho is also implementing supply-chain measures to offset tariff-related cost pressures, while the wind-down of its U.S. Donor Screening business, expected to be substantially complete by mid-2026, and normalized working capital are projected to support stronger free cash flow generation in the second half of 2026.
Mixed Q1 Results: QuidelOrtho ended the first quarter of 2026 with mixed results, where revenues surpassed the Zacks Consensus Estimate, but earnings missed significantly. The company continued to witness strength in its Labs and Immunohematology business units, while solid growth across Latin America and resilient performance in EMEA and JPAC were encouraging.
However, persistent weakness in respiratory testing continued to weigh heavily on the top line, with Point of Care and Donor Screening businesses also posting sharp declines. The company’s bottom line deteriorated year over year, while gross and operating margins contracted significantly due to lower volumes and an unfavorable business mix.
Factors That May Offset QDEL’s GainsOverdependence on Respiratory Segment: Respiratory testing remains a key swing factor for QuidelOrtho’s revenues and profitability despite the post-pandemic reset. First-quarter 2026 results were pressured by a milder and shorter respiratory season, with influenza-like illness visits declining roughly 30% year over year and respiratory revenues totaling $68 million. While management indicated that testing protocols and market share remained stable, suggesting the weakness was demand-driven rather than competitive, the lower respiratory contribution reduced product mix and contributed to a 630-basis point decline in adjusted gross margin.
For 2026, the company assumes a 50-55 million annual flu market and flat COVID revenues compared with 2025, but still expects full-year respiratory revenues to decline, implying that even modest shifts in seasonality or testing volumes could continue to create significant variability in quarterly results and cash generation.
Estimate TrendQuidelOrtho is witnessing a negative estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has moved south to $1.87 per share.
The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $614.6 million, indicating 0.12% growth from the year-ago quarter’s reported number.
Other Key PicksSome other top-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
Investor litigation firm Kaskela Law announces that it is investigating QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) on behalf of the company’s long-term investors.
Click here for additional information: https://kaskelalaw.com/case/quidelortho-corp/
Recently a securities fraud complaint was filed against QuidelOrtho on behalf of certain investors who purchased shares of the company’s stock between February 17, 2022 and April 1, 2024 (the “Wrongdoing Period”). According to the complaint, during the Wrongdoing Period, the defendants made a series of materially false and misleading statements to investors concerning QuidelOrtho’s business, operations, and prospects.
As further detailed in the complaint, on February 13, 2024, QuidelOrtho issued a press release reporting disappointing quarterly financial results, and “slashed” its 2024 financial forecasts, including a dramatic cut to its COVID-19 revenue forecast. On this news, shares of the company’s stock fell $21.50 per share, or 32% in value, to close on February 14, 2024 at $45.27 per share, on unusually heavy trading volume.
The investigation seeks to determine whether the members of QuidelOrtho’s board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.
Current QuidelOrtho shareholders who purchased or acquired their QDEL shares prior to February 13, 2024 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their legal rights and options at (484) 229 – 0750, by email at [email protected], or online at:
https://kaskelalaw.com/case/quidelortho-corp/
ABOUT KASKELA LAW:
Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis (i.e., the firm’s clients are never responsible for any out-of-pocket costs for legal representation). Since 2020, the firm has helped to recover over $500 million for investors. For additional information about Kaskela Law LLC, including the firm’s recent notable recoveries for investors, please visit www.kaskelalaw.com.
This communication may constitute attorney advertising in certain jurisdictions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260723699295/en/
PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/quidelortho-corp/ Recently a securities fraud complaint was filed against QuidelOrtho on behalf of certain investors who purchased shares of the company's stock between February 17, 2022 and April 1, 2024 (the “Wrongdoing Peri.
, /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 59 of its Science Bytes podcast examining how the drug overdose landscape continues to evolve and what laboratory and emergency department professionals need to know to support patient care. Based on new guidance from the Association for Diagnostics and Laboratory Medicine (ADLM), the episode explores the growing complexity of toxicology testing amid counterfeit medications, polysubstance use and emerging synthetic opioids.
QuidelOrtho Science Bytes | Episode 59 Hosted by Josh Casey, the episode features Vonda McAllister, Director of Global Product Management at QuidelOrtho. Together, they discuss encouraging declines in overdose mortality while highlighting the ongoing challenges facing clinicians and laboratorians as the illicit drug supply becomes increasingly unpredictable.
Key Insights:
U.S. overdose deaths declined for a third consecutive year in 2025, signaling progress in the fight against the opioid crisis Counterfeit medications remain a significant threat, with millions of fentanyl-laced pills seized annually Polysubstance use is increasingly common, creating more complex clinical presentations for patients Emerging synthetic opioids such as nitazenes are attracting attention due to their potency and limited detectability in routine screening New ADLM guidance emphasizes collaboration between laboratories and emergency departments to improve toxicology testing and interpretation Despite progress in reducing overdose deaths, the discussion underscores that the crisis has not disappeared. Instead, it has evolved into a broader challenge requiring ongoing awareness, education and collaboration across the healthcare continuum.
The episode also highlights the critical role laboratories play in helping clinicians understand toxicology results, select appropriate testing strategies and make informed patient care decisions in rapidly changing drug environments.
Listen to the latest episode of the QuidelOrtho Science Bytes podcast on major streaming platforms or at: https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
The Zacks Medical – Products industry is navigating an uneven operating environment where macroeconomic headwinds are colliding with strong structural healthcare demand. Rising tariffs, persistent inflation in electronic components, freight and raw materials, as well as supply-chain normalization challenges are pressuring margins and forcing manufacturers to rely on pricing actions, productivity initiatives and supply-chain diversification. Operational disruptions, product remediation efforts and elevated R&D spending are also weighing on near-term profitability.
Despite these challenges, underlying demand remains resilient, supported by healthy procedural volumes, hospital capital spending, aging demographics and growing prevalence of chronic diseases. At the same time, rapid innovation across AI-enabled diagnostics, robotic-assisted surgery, cardiovascular interventions and digital care platforms is creating new growth opportunities and expanding addressable markets.
These contrasting forces suggest that while the industry's near-term outlook remains constrained by cost pressures, companies with differentiated technologies, innovation pipelines and disciplined execution are best positioned to outperform.
Terumo (TRUMY - Free Report) , QuidelOrtho (QDEL - Free Report) , Lumexa Imaging Holdings, Inc. (LMRI - Free Report) and Brainsway (BWAY - Free Report) are countering industry pressures through pricing actions, cost-control initiatives, differentiated innovation pipelines, and focused execution across their core growth franchises and rising demand for advanced diagnostic solutions.
Industry Description The industry includes companies that provide medical products and cutting-edge technologies for healthcare services, including Abbott Laboratories, Stryker and Boston Scientific. These companies are primarily focused on research and development and cater to vital therapeutic areas like cardiovascular, nephrology and urology devices.
The increase in procedure volumes is driving sales, particularly for surgical products and services. At the same time, cost-cutting measures are helping companies improve their bottom-line performance.
However, the industry’s profitability picture is under significant strain. War-related disruptions are likely to cut into margins and may force companies into another complex and costly supply-chain restructuring.
Major Trends Shaping the Future of the Medical Products Industry Innovation Continues to Create New Growth Engines: The industry's strongest growth driver remains continuous product innovation. Companies are accelerating investments in AI-powered imaging, robotic-assisted surgery, electrophysiology, structural heart therapies, diabetes care and digital health platforms to capture expanding clinical opportunities. Per the FDA list, there are currently more than 1,500 FDA-cleared AI/ML-enabled devices, and the figure is likely to increase as several medical device makers are actively developing such devices for efficient and faster diagnosis and treatment. Remote patient monitoring platforms are projected to reach $30.9 billion by 2026-end and $110.7 billion by 2033, per a Grand View research report.
New product launches, broader regulatory approvals and increasing physician adoption are helping companies penetrate higher-growth therapeutic categories while improving procedural efficiency and patient outcomes. Robust innovation pipelines are also supporting pricing power and strengthening long-term competitive positioning across the medical products landscape.
Migration to Ambulatory and Home-Based Care: The U.S. market is experiencing a sustained shift from inpatient hospital settings to ASCs and home-based monitoring. The ASC market is set to reach $205 billion by 2030, per a Grand View Research report, driven by procedure cost efficiency, CMS policy changes and expanded device portfolios tailored for outpatient use. Coupled with increased adoption of wearables and connected devices, care decentralization is reshaping technology requirements, pricing structures and competitive dynamics for device makers.
Accelerating Innovation in Robotics and Specialty Therapeutics: Surgical robotics and specialty cardiovascular interventions are driving the next wave of value creation, with robotics poised to witness a 10.5% CAGR, per a Grand View Research report, and pulsed-field ablation transforming electrophysiology standards.
Intuitive Surgical’s platform evolution, entry of versatile competitors and expansion of structural heart solutions (TMVR, PFA) highlight a winner-take-all dynamic. Innovation, clinical outcome evidence and ecosystem lock-in are creating durable advantages in profitability and return on invested capital (ROIC), while commoditized hardware businesses remain under pressure.
Procedure Recovery and Hospital Spending Support Demand: Healthy procedure volumes, favorable demographic trends and resilient hospital capital spending continue to support industry growth. Aging populations, the rising prevalence of chronic diseases and the growing adoption of minimally invasive procedures are driving sustained demand across the cardiovascular, orthopedic, neuromodulation and diagnostic markets. Hospitals also continue to invest in advanced imaging systems, robotics and workflow automation to improve productivity and patient care, providing manufacturers with strong recurring demand despite broader macroeconomic uncertainty.
Tariffs and Cost Inflation Continue to Pressure Margins: The industry's biggest challenge remains rising input costs stemming from tariffs, inflation and supply-chain pressures. Higher prices for semiconductors, metals, freight and other critical components are squeezing margins, while some companies continue to navigate operational disruptions and remediation costs. Although manufacturers are offsetting part of the pressure through pricing actions, productivity initiatives and supply-chain optimization, elevated costs are likely to remain a key headwind for earnings growth in the near term.
Zacks Industry Rank The Zacks Medical Products industry falls within the broader Zacks Medical sector.
It currently carries a Zacks Industry Rank #169, which places it in the bottom 32% of more than 245 Zacks industries.
The group’s Zacks Industry Rank, which is basically the average of the Zacks Rank of all member stocks, indicates dull near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Before we present a few medical product stocks that you may want to consider for your portfolio, let’s take a look at the industry’s recent stock-market performance and valuation picture.
Industry Performance The industry has underperformed its own sector as well as the Zacks S&P 500 composite over the past year.
Stocks in this industry have collectively declined 26.1% against the Zacks Medical sector’s rise of 12.7%. The S&P 500 has increased 21.1% in the same time frame.
One-Year Price Performance
Industry's Current Valuation On the basis of the forward 12-month price-to-earnings (P/E), which is commonly used for valuing medical stocks, the industry is currently trading at 16.3X compared with the S&P 500’s 20.7X and the sector’s 21.1X.
Over the past five years, the industry has traded as high as 27.4X and as low as 15.3X, with the median being 21.8X, as the charts show.
Price-to-Earnings Forward Twelve Months (F12M)
Price-to-Earnings Forward Twelve Months (F12M)
4 Potential Winning Medical Product Stocks BrainsWay continues to emerge as one of the industry's fastest-growing niche medtech companies, driven by expanding adoption of its Deep TMS platform. Strong system placements, a growing installed base, recurring multi-year contracts and improving reimbursement coverage are supporting sustained revenue visibility.
Additional catalysts include expanding clinical indications, the SWIFT protocol, strategic investments in mental health networks and Neurolief, and a large untapped market opportunity for non-invasive neuromodulation therapies. Still, continued investment in commercialization, reimbursement expansion and broader physician adoption remain necessary, while geopolitical and supply-chain uncertainties could modestly affect execution.
For 2026, BrainsWay has guided revenues of $66-$68 million (27-30% growth), operating margin of 13-14% and adjusted EBITDA of $12-$14 million, indicating strong bottom-line expansion.
For this Israel-based company, the Zacks Consensus Estimate for fiscal 2026 revenues is pegged at $68.5 million, projecting 31.2% growth. The consensus mark for EPS is pinned at 33 cents per share, implying an 8.3% decline year over year. The company delivered a trailing four-quarter average earnings surprise of 72.23%.
Presently, the company sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Price and Consensus: BWAY
Terumo appears well positioned for a strong second half of 2026, supported by broad-based growth across its Cardiac & Vascular, Neuro, Blood & Cell Technologies and Pharmaceutical Solutions businesses. Continued demand in North America, pricing actions, expanding neurovascular adoption, growth in CDMO and PLAJEX businesses, and the first full-year contribution from Terumo Organ Technologies should sustain high-single-digit revenue growth while profit expands faster than sales. The absence of large one-time restructuring charges also strengthens earnings visibility.
However, U.S. tariffs, higher raw material costs and geopolitical uncertainty remain key risks, although management expects pricing and cost-control initiatives to offset much of the pressure.
The company expects revenues and operating profit to grow 8% and 20%, respectively, in 2026. For this Japanese company, the Zacks Consensus Estimate for 2026 revenues of $7.69 billion indicates year-over-year growth of 2.4%. The consensus estimate for earnings of 70 cents per share indicates an improvement of 14.8%. Presently, the company carries a Zacks Rank #2 (Buy).
Price and Consensus: TRUMY
Despite a difficult first quarter, QuidelOrtho's long-term outlook is improving as its growth increasingly shifts beyond seasonal respiratory testing. The LEX Diagnostics acquisition strengthens its point-of-care molecular diagnostics portfolio, while the U.S. launch of the high-sensitivity troponin assay and international rollout of the VITROS 450 platform should support higher laboratory revenues in the second half.
Management also expects margin expansion through restructuring, procurement savings and facility consolidation. Nevertheless, a weak respiratory season, China IVD pricing reforms and geopolitical disruptions affecting Middle East orders could continue to pressure near-term growth and profitability.
For this San Dieogo, CA-based company, the Zacks Consensus Estimate for 2026 revenues is pegged at $2.68 billion, suggesting a decline of 1.8%. The consensus mark for earnings per share (EPS) is pinned at $1.87, indicating a decline of 11.8%. However, revenues and earnings are likely to improve 2.7% and 25.7%, respectively, in 2027. The company delivered a trailing four-quarter average negative earnings surprise of 15.66%. Presently, the company carries a Zacks Rank of 2.
Price and Consensus: QDEL
Lumexa's growth prospects remain supported by structural shifts toward outpatient imaging and rising demand for advanced diagnostic modalities. Robust PET and MRI growth, accelerating de novo center openings, tuck-in acquisitions, expanding joint ventures with health systems and increasing adoption of AI-enabled imaging solutions provide multiple growth levers for the second half of 2026.
Favorable industry trends, including aging demographics, preventive screening and site-of-care migration, further strengthen the outlook. However, weather-related volume disruptions, seasonal payer mix changes and cybersecurity-related compliance costs could create intermittent operational headwinds despite management's strong execution.
For this Raleigh, NC-based company, the Zacks Consensus Estimate for 2026 revenues is pegged at $1.07 billion, projecting 298% growth. The consensus mark for EPS is pinned at 77 cents, implying a 302.6% improvement year over year. The company delivered a trailing four-quarter average negative earnings surprise of 685%. Presently, it carries a Zacks Rank #2.
, /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL)("QuidelOrtho"), a leading global provider of diagnostic solutions, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of restricted stock units ("RSUs") with respect to 356,555 shares of the Company's common stock (the "Inducement Grant") to Micah Young, the Company's Chief Financial Officer and principal financial officer. The Inducement Grant was granted pursuant to the Company's 2026 Inducement Plan and as an inducement material to Mr. Young's entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2026 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of QuidelOrtho, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with QuidelOrtho, pursuant to Nasdaq Listing Rule 5635(c)(4).
The RSUs were granted with a grant date of July 15, 2026, and will vest in equal annual installments on the first three anniversaries of the grant date, subject to Mr. Young's continued employment with the Company through each applicable vesting date. The RSUs are subject to the terms and conditions of the 2026 Inducement Plan and the terms and conditions of a RSU award agreement covering the grant.
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Short position through short-selling of the stock, or purchase of put options or similar derivatives in QDEL over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
QuidelOrtho (QDEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Seasoned medical technology finance executive brings more than two decades of leadership at global public companies
, /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho" or the "Company"), a leading global provider of diagnostic solutions, today announced the appointment of Micah Young as Chief Financial Officer, effective July 6, 2026. Mr. Young will succeed Joseph M. Busky, who previously announced his retirement as Chief Financial Officer and will serve in an advisory role to support a smooth transition.
Micah Young, Chief Financial Officer, QuidelOrtho "Micah is an accomplished public-company CFO with deep medical technology expertise and a strong track record of improving financial performance, strengthening cash flow and driving disciplined execution," said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho. "His leadership across business strategy, capital allocation, investor relations and financial operations will be valuable as we execute our priorities to improve profitability, enhance cash generation and create long-term shareholder value. We are excited to welcome Micah to the QuidelOrtho leadership team."
Mr. Blaser added, "We thank Joe for his leadership and many contributions to QuidelOrtho. He has played an important role in strengthening our financial discipline and guiding the Company through a period of significant transformation. We appreciate his support of a seamless transition and wish him the very best."
Mr. Young most recently served as Executive Vice President and Chief Financial Officer of Masimo Corporation, a global medical technology company. He joined Masimo as CFO in 2017 and helped lead the company through a period of strategic transformation, operational improvement, disciplined capital allocation, enhanced investor engagement and significant transaction activity. Previously, he held progressively senior finance roles at NuVasive, Inc. and finance and accounting roles at Zimmer Holdings, Inc., after beginning his career at Deloitte & Touche LLP. Mr. Young holds a Bachelor of Science in Accounting and Criminal Justice from Indiana Wesleyan University and is a Certified Public Accountant (inactive).
"I am honored to join QuidelOrtho at an important point in the Company's evolution," said Mr. Young. "QuidelOrtho has a strong global portfolio, a meaningful mission and clear opportunities to enhance execution and performance. I look forward to working with Brian, the Board and the leadership team to strengthen operational discipline, support growth and create sustainable value for shareholders, customers and patients."
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Key Takeaways QuidelOrtho is poised for growth on its strong product portfolio and cost-saving progress.QDEL's Labs business leads first-quarter revenues, with Immunohematology and Point of Care adding support.Respiratory testing remains a key swing factor as lower demand pressures revenues and margins. QuidelOrtho Corporation (QDEL - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by mixed first-quarter 2026 results, is expected to contribute further, along with progress in cost-saving initiatives. However, risks due to overdependence on the respiratory business persist.
This Zacks Rank #3 (Hold) company has lost 50.5% in the year-to-date period compared with the 23.2% decline of the industry. The S&P 500 has witnessed 10.5% growth in the said time frame.
The renowned rapid diagnostic testing solutions provider has a market capitalization of $993.5 million. QuidelOrtho’s earnings yield of 13.8% compares favorably with the industry’s 3.5%. The company surpassed the Zacks Consensus Estimate in two of the trailing four quarters, missed once and met estimates once, delivering an average negative surprise of 15.7%.
Image Source: Zacks Investment Research
Factors Favoring QDEL’s GrowthRobust Product Portfolio: QuidelOrtho’s diversified portfolio across Labs, Immunohematology, Point of Care and Molecular Diagnostics helps cushion demand fluctuations across testing categories. In the first quarter of 2026, Labs remained the largest revenue contributor at $353.1 million, followed by Immunohematology at $138.3 million and Point of Care at $112.8 million.
The company's Sofia platform and QuickVue franchise continue to provide scale in respiratory testing, with management noting stable market share during the quarter. For 2026, QuidelOrtho expects a typical flu season and stable testing protocols, with guidance based on a 50-55 million annual flu testing market and flat COVID-related revenues compared with 2025.
Growth initiatives remain focused on menu expansion and international penetration, with the U.S. launch of its high-sensitivity troponin assay already reaching more than 300 customer shipments and the rollout of the VITROS 450 system targeting lower-volume laboratories, which management believes can drive mid-single-digit long-term growth in the Labs business.
Progress on Cost-Saving Initiatives: QuidelOrtho is leveraging restructuring and productivity initiatives to expand margins and support investments in new platforms. In first-quarter 2026, adjusted operating expenses declined 2% year over year, led by a 19% reduction in R&D spending, while management reaffirmed its full-year adjusted EBITDA margin target of approximately 23%.
Through its Optimization Plan, the company is pursuing procurement efficiencies, facility consolidation and distribution rationalization, expecting around $50 million in net cost savings through 2027 despite cumulative pre-tax charges of about $100 million. QuidelOrtho is also implementing supply-chain measures to offset tariff-related cost pressures, while the wind-down of its U.S. Donor Screening business, expected to be substantially complete by mid-2026, and normalized working capital are projected to support stronger free cash flow generation in the second half of 2026.
Mixed Q1 Results: QuidelOrtho ended the first quarter of 2026 with mixed results, where revenues surpassed the Zacks Consensus Estimate, but earnings missed significantly. The company continued to witness strength in its Labs and Immunohematology business units, while solid growth across Latin America and resilient performance in EMEA and JPAC were encouraging.
However, persistent weakness in respiratory testing continued to weigh heavily on the top line, with Point of Care and Donor Screening businesses also posting sharp declines. The company’s bottom line deteriorated year over year, while gross and operating margins contracted significantly due to lower volumes and an unfavorable business mix.
Factors That May Offset the Gains for QDELOverdependence on Respiratory Segment: Respiratory testing remains a key swing factor for QuidelOrtho’s revenues and profitability despite the post-pandemic reset. First-quarter 2026 results were pressured by a milder and shorter respiratory season, with influenza-like illness visits declining roughly 30% year over year and respiratory revenues totaling $68 million. While management indicated that testing protocols and market share remained stable, suggesting the weakness was demand-driven rather than competitive, the lower respiratory contribution reduced product mix and contributed to a 630-basis point decline in adjusted gross margin.
For 2026, the company assumes a 50-55 million annual flu market and flat COVID revenues versus 2025, but still expects full-year respiratory revenues to decline, implying that even modest shifts in seasonality or testing volumes could continue to create significant variability in quarterly results and cash generation.
Estimate TrendQuidelOrtho is witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings has remained stable at $2.01 per share.
The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $625.4 million, indicating 1.9% growth from the year-ago quarter’s reported number.
Key PicksSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, currently sporting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
On June 16, 2026, QuidelOrtho Corp QDEL shares fell 3.3%, bringing the current price to $14.13. The stock has experienced significant volatility, with a 52-week range between $9.92 and $35.58.
GF Value™ verdict: Current price of $14.13 is 62.1% below the GF Value™ estimate of $37.27.GF Score™ of 48/100 indicates an average performance compared to peers.Notable signal: No insider transactions in the last 3 months suggest a lack of insider confidence in the short term. Is QDEL Overvalued or Undervalued? The current price of QuidelOrtho Corp QDEL at $14.13 presents a significant discount when compared to the GF Value™ estimate of $37.27, indicating that the stock may be undervalued by approximately 62.1%. This considerable margin of safety can attract value-focused investors looking for potentially lucrative opportunities. However, caution is warranted as the GF Valuation label suggests that QDEL might represent a possible value trap, implying that the stock could be undervalued due to ongoing financial challenges rather than strong fundamentals. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
While the substantial price difference between the current market price and the GF Value™ could indicate an attractive investment opportunity, prospective buyers should also consider the underlying financial health of the company, as indicated by its low GF Score™ and other valuation metrics.
How Does QDEL's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 7.7x 6.8x Currently, QuidelOrtho's forward P/E ratio of 7.7x is higher than its 5-year median P/E of 6.8x, suggesting that the stock is trading above its historical valuation levels. This P/E analysis does not align with the GF Value™ verdict, which indicates a significant undervaluation, pointing out a potential disconnect between market perception and intrinsic value.
What Does QDEL's GF Score™ Tell Us? Metric Rating GF Score™ 48 Financial Strength 3/10 Profitability 5/10 Growth 2/10 Valuation 2/10 Momentum 2/10 The GF Score™ of 48/100 indicates an average rating, with notable weaknesses in the Growth (2/10), Valuation (2/10), and Momentum (2/10) categories. In contrast, Profitability holds a more favorable score of 5/10, suggesting that while the company may have some profitability, its overall growth prospects and valuation metrics are underwhelming. This combination of scores suggests that while the stock may offer some value based on its current pricing, underlying financial issues and lack of momentum raise red flags for long-term performance.
What Are Insiders Doing with QDEL Stock? Currently, there have been no insider transactions in the last three months for QuidelOrtho Corp QDEL . This lack of activity may reflect a cautious approach from insiders regarding the company's future performance, indicating that they may not see immediate catalysts for growth or improvement in the stock's value.
What This Means for Investors Based on the GF Value™ assessment and the current price performance, QuidelOrtho Corp QDEL appears to be undervalued at $14.13 compared to the GF Value™ estimate of $37.27. However, the company’s low GF Score™ and potential value trap status suggest that investors should proceed with caution and conduct thorough due diligence before making any decisions.
For the complete analysis, visit the QuidelOrtho Corp QDEL stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is QDEL's GF Score™?
The GF Score™ for QuidelOrtho Corp QDEL is 48/100, indicating an average performance compared to its peers based on various key metrics.
Is QDEL overvalued or undervalued?
QDEL is considered undervalued based on the GF Value™ estimate, which suggests a significant margin of safety compared to the current trading price.
What is QDEL's P/E ratio?
QDEL's forward P/E ratio is 7.7x, which is above its historical median P/E of 6.8x, indicating that the stock is currently trading at a higher valuation compared to its historical levels.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Weak Flu Season, China Snags Weigh On Q1 SalesThe diagnostic healthcare products maker reported preliminary unaudited revenue in the range of $615 million to $620 million for the first quarter, compared to the consensus of $680.59 million.
The results reflect a weaker respiratory season, with U.S. Influenza-like Illness visits down about 30% compared to the prior-year period, along with slower China distributor sales and delays in certain EMEA orders, the company said.
The San Diego, California-based company also expects free cash flow to be negative in the first half of 2026, with first-quarter free cash flow projected in the range of $(65) million to $(70) million.
Still, the full-year 2026 free cash flow is expected to be positive.
Analyst Flags Execution Risks Despite Management ConfidenceWilliam Blair said management still believes hitting the low end of its guidance is achievable following the update, but analyst Andrew Brackmann expects investors to remain skeptical.
Reaching the low end would depend on several favorable assumptions: a typical fourth-quarter respiratory season, no meaningful reimbursement changes in China—where visibility remains limited—and a normalization in the Middle East, which accounts for 3%–4% of sales and has yet to show improvement despite the ceasefire.
China Uncertainty And Segment Weakness Cloud OutlookWilliam Blair expects estimates to fall below the guidance range, particularly given ongoing uncertainty in China. Any disruption in that high-margin segment could have an outsized impact on earnings.
While factors outside management's control largely drove the first-quarter miss, the analyst believes investors will focus on broader risks.
The core business, representing about 70% of revenue, remains solid, but weakness in the remaining 30% is weighing on overall financial performance. Elevated debt levels and limited near-term free cash flow compound this.
The stock's decline reflects continued concern around the China business, where management has limited control.
Potential reimbursement changes add another layer of uncertainty, with unclear timing and financial impact.
QDEL Price Action: QuidelOrtho shares were down 32.13% at $11.87 at the time of publication on Thursday. The stock is trading at a new 52-week low, according to Benzinga Pro data.
Market News and Data brought to you by Benzinga APIs
QuidelOrtho's (QDEL) reported weakness is concentrated in post-COVID Point of Care and the deliberate US donor-screening exit. However, the rest of their portfolio is actually growing. Labs is the primary revenue engine, contributing 55% of sales in 2025. Likewise, Immunohematology also expanded and supports a healthier underlying mix.
– Marks a Milestone in QuidelOrtho's Plans to Accelerate Growth in Point-of-Care Molecular Diagnostics –
– Expands Portfolio with Ultra-Fast PCR Platform Designed to Deliver Results in Approximately Ten Minutes or Less –
– Company Expects to Initiate U.S. Commercial Launch of the LEX VELO System Later This Year –
, /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today it has completed the acquisition of LEX Diagnostics ("LEX") for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration ("FDA") 510(k) clearance and CLIA waiver in February 2026.
LEX Diagnostics The LEX VELO System is a breakthrough molecular diagnostics platform that is designed to deliver highly sensitive, multiplex RT-PCR testing for Influenza A, Influenza B and COVID-19 directly from a swab sample in approximately six to ten minutes. Its proprietary cartridge-based design supports rapid clinical decision-making in decentralized care environments by eliminating the need for external liquid handling; delivering speed, reliability and ease of use. The acquisition of LEX marks a critical milestone in QuidelOrtho's molecular diagnostics strategy to accelerate its growth in point-of-care molecular diagnostics by acquiring innovative technology within one of the fastest-growing segments of the diagnostics market.
"The FDA clearance of the LEX VELO System and the completion of our acquisition of LEX mark a pivotal moment for QuidelOrtho and for our customers," said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho. "This ultra-fast PCR platform is designed to deliver lab-quality results in minutes and fits seamlessly into point-of-care workflows. It empowers providers to act faster, make better-informed decisions and ultimately improve patient outcomes. It also reflects our long-term commitment to bringing advanced diagnostics closer to the patient."
Completing the acquisition of LEX expands QuidelOrtho's molecular diagnostics portfolio while complementing the Company's leadership positions in immunoassay, clinical chemistry and transfusion medicine. It reinforces QuidelOrtho's ability to deliver integrated diagnostic solutions across the continuum of care, from point of care to hospital, lab to clinic.
"LEX achieved an extraordinary milestone with FDA clearance and CLIA waiver of the LEX VELO System," said Ed Farrell, Chief Executive Officer of LEX. "We are proud to join QuidelOrtho and to bring this technology to customers worldwide. We believe we can redefine what is possible in point-of-care molecular diagnostics."
QuidelOrtho expects to initiate the U.S. commercial launch of the LEX VELO System later this year. Global expansion is expected to follow, subject to local regulatory approvals.
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho's commercial and other strategic goals, and other future plans, objectives, strategies, expectations and intentions. Without limiting the foregoing, the words "may," "will," "could," "would," "should," "might," "expect," "anticipate," "believe," "estimate," "plan," "intend," "goal," "project," "strategy," "future," "continue," "aim," "strive," "seek" or similar words, expressions or the negative of such terms or other comparable terminology are intended to identify forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho's management as of the date of this press release and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among others, could cause actual results or outcomes to differ from those set forth or implied in the forward-looking statements: fluctuations in demand for QuidelOrtho's non-respiratory and respiratory products; supply chain, production, logistics, distribution and labor disruptions and challenges, including disruptions and challenges related to the 2026 Middle East conflict; inability to successfully identify, consummate or realize the anticipated benefits of strategic transactions, strategic restructurings, divestitures, spin-offs or discontinuances of certain business operations, or debt financings, on the anticipated timelines, or at all; delays in the development of or failures or delays in the receipt of approvals for new or enhanced products; failure of new products and services to be commercially viable or accepted; changes in reimbursement rates for QuidelOrtho's products, including reimbursement rate reductions proposed by the China National Health Security Administration; and other macroeconomic, geopolitical, market, business, competitive and/or regulatory factors affecting the business of QuidelOrtho generally, including those arising from the effects of announced or future or amended tariffs, trade policies, investigations and global trade relations, as well as those discussed in QuidelOrtho's Annual Report on Form 10-K for the fiscal year ended December 28, 2025 and subsequent reports filed with the Securities and Exchange Commission, including under Part I, Item 1A, "Risk Factors" of the Form 10-K. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date of this press release. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this press release, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.
CAMBRIDGE, England--(BUSINESS WIRE)--TTP today announced the acquisition by QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, of LEX Diagnostics Limited, a UK-based molecular diagnostics company and a spin-out of TTP Group.
Founded in 2020, LEX Diagnostics originated from a TTP innovation programme to translate a breakthrough in ultra-fast thermal control into a commercially viable diagnostic solution. This work led to the development of a point-of-care molecular testing platform capable of delivering PCR results in minutes.
“At TTP, we identified the opportunity for ultra-fast thermal cycling to unlock the real potential of PCR at the point-of-care,” said Dr Andrew Baker-Campbell, Chair and founding CEO of LEX Diagnostics. “That insight led our scientists and engineers to invent the core technology behind LEX Diagnostics, and TTP spun out the company to bring lab-quality PCR results to clinicians in minutes.”
In February 2026, LEX Diagnostics received U.S. Food and Drug Administration (FDA) 510(k) clearance and CLIA waived status for its VELO system, which provides lab-quality results of Flu A, Flu B and COVID-19 directly from a swab sample. With positive results available in as little as 6 minutes and negative results in under 10 minutes, the system is designed to support faster diagnosis and more immediate clinical decisions by bringing high-quality molecular PCR testing closer to patients.
“LEX Diagnostics is a great example of how TTP turns breakthrough science into valuable new businesses. We have a long history of partnering with industry to incubate technologies from first principles and scaling them into impactful companies,” said Dr Sam Hyde, CEO of TTP Group. “This acquisition demonstrates the strength of that model and we’re proud to see LEX Diagnostics and the team delivering meaningful advances in patient care, achieving this important milestone and look forward to their continued progress within QuidelOrtho.”
About TTP Group
TTP Group is an independent technology company where scientists and engineers partner with ambitious clients to invent, design, and engineer breakthrough technologies and products that meet real-world needs and make a meaningful impact. Working across sectors including healthcare, medtech, life sciences, communications, defence and industrials, TTP combines deep technical expertise with commercial insight to turn complex challenges into successful products. Alongside client work, TTP has a strong track record of creating and scaling spin-out companies, taking innovations from initial concept through to market adoption and successful exit.
About LEX Diagnostics
LEX Diagnostics is a molecular diagnostics company focused on advancing point-of-care testing through its ultra-fast platform. Founded in 2020 as a spin-out from TTP Group, it has developed proprietary thermal cycling technology enabling rapid, highly sensitive molecular testing. Its VELO system brings PCR-level accuracy to urgent care centres, physician office laboratories and pharmacies, delivering results in minutes and supporting faster diagnosis and treatment decisions. In February 2026, LEX Diagnostics received U.S. Food and Drug Administration (FDA) 510(k) clearance and CLIA waived status for its VELO system.
QuidelOrtho (NASDAQ:QDEL – Get Free Report) and United Health Products (OTCMKTS:UEEC – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations.
Earnings & Valuation This table compares QuidelOrtho and United Health Products”s gross revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio QuidelOrtho $2.73 billion 0.30 -$1.13 billion ($16.66) -0.71 United Health Products N/A N/A -$2.67 million ($0.01) -9.00 United Health Products has lower revenue, but higher earnings than QuidelOrtho. United Health Products is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations This is a breakdown of recent ratings and target prices for QuidelOrtho and United Health Products, as reported by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score QuidelOrtho 3 2 1 0 1.67 United Health Products 0 0 0 0 0.00 QuidelOrtho presently has a consensus target price of $28.25, indicating a potential upside of 137.39%. Given QuidelOrtho’s stronger consensus rating and higher probable upside, equities analysts plainly believe QuidelOrtho is more favorable than United Health Products.
Profitability This table compares QuidelOrtho and United Health Products’ net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets QuidelOrtho -41.46% 5.91% 2.37% United Health Products N/A N/A -1,787.77% Insider and Institutional Ownership 99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 0.1% of United Health Products shares are held by institutional investors. 0.8% of QuidelOrtho shares are held by insiders. Comparatively, 1.5% of United Health Products shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Volatility and Risk QuidelOrtho has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, United Health Products has a beta of -0.69, suggesting that its share price is 169% less volatile than the S&P 500.
Summary QuidelOrtho beats United Health Products on 9 of the 13 factors compared between the two stocks.
About QuidelOrtho (Get Free Report)
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
About United Health Products (Get Free Report)
United Health Products, Inc. develops, manufactures, and markets hemostatic gauze products for the healthcare and wound care sectors in the United States. The company offers HemoStyp hemostatic gauze products to absorb exudate/drainage from superficial wounds, as well as helps in controlling bleeding. It serves hospitals and surgery centers, clinics and physicians, military medical care providers, hemodialysis centers, nursing homes and assisted living, and veterinary hospitals; and EMS, fire departments, and other first responders, as well as dental, oral, and maxillofacial surgery offices. The company was formerly known as United EcoEnergy Corp. and changed its name to United Health Products, Inc. in September 2010. United Health Products, Inc. was incorporated in 1997 and is headquartered in Mount Laurel, New Jersey.
Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECaprock Group LLC Increases Stock Position in Marriott International, Inc. $MAR
NEXT HEADLINE »Robinhood Asset Management LLC Purchases Shares of 58,520 Microsoft Corporation $MSFT
, /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 57 of its Science Bytes podcast, focusing on evolving syphilis trends in the United States and the rise of congenital syphilis cases despite declines in early-stage infections.
Andrea Ott‑Vasconi, Director of Scientific Affairs and Regulatory, QuidelOrtho
QuidelOrtho Science Bytes - Episode 57 Hosted by Josh Casey, the episode features Andrea Ott‑Vasconi, Director of Scientific Affairs and Regulatory at QuidelOrtho, who breaks down what CDC data reveals, why congenital syphilis continues to rise and how diagnostic strategies and healthcare workflows can close critical screening gaps, especially during pregnancy.
While provisional data show a second consecutive year of decline in primary and secondary syphilis cases, congenital syphilis cases reached nearly 4,000 in 2024. Because congenital syphilis is completely preventable with timely diagnosis and treatment during pregnancy, the episode highlights missed screening opportunities and actionable steps health systems can take now.
Key Insights:
Diverging trends in syphilis: Early-stage syphilis is declining, but congenital syphilis continues to rise due to missed or late screening Why repeat testing matters: A single early prenatal test misses infections acquired later in pregnancy Understanding testing strategies: How treponemal and non‑treponemal tests work together to identify active infection Screening beyond prenatal care: Emergency departments and opt‑out screening play a critical role in identifying asymptomatic infections Actionable steps for health systems: Universal repeat testing in pregnancy, EHR prompts and treating every pregnancy-related encounter as a screening opportunity Listen to the latest episode of the QuidelOrtho Science Bytes podcast on major streaming platforms or at: https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
On April 27, 2026, QuidelOrtho Corp QDEL shares rose 6.1% today, currently trading at $12.29. The stock has experienced a volatile year, with a 52-week range between $10.86 and $38.99.
GF Value™ verdict: Current price of $12.29 is 69.0% below the GF Value™ of $39.69.GF Score™ of 60/100 indicates the stock is rated above average.Notable signal: Insider activity shows that insiders have bought $0.6 million worth of shares in the last 3 months, with no selling. Is QDEL Overvalued or Undervalued? QuidelOrtho Corp QDEL presents an intriguing valuation scenario as its current price of $12.29 is significantly below the GF Value™ of $39.69, indicating that the stock is 69.0% undervalued. This substantial margin of safety could suggest an opportunity for investors, especially in light of the company's GF Valuation label, which categorizes it as a possible value trap. This label serves as a cautionary note, urging potential investors to proceed with care.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. While the undervaluation may attract interest, it is crucial to consider the risks associated with the company’s current financial condition and market sentiment.
How Does QDEL's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 5.8x 6.6x Currently, QDEL's forward P/E of 5.8x is below its 5-year median P/E of 6.6x, indicating that the stock is trading at a lower valuation compared to its historical averages. This P/E analysis aligns with the GF Value™ verdict of undervaluation, suggesting that QDEL may offer potential upside if the company can stabilize its operations and improve market perception.
What Does QDEL's GF Score™ Tell Us? Metric Rating GF Score™ 60/100 Financial Strength 3/10 Profitability 6/10 Growth 3/10 Valuation 2/10 Momentum 4/10 The GF Score™ of 60/100 reflects above-average potential, but also reveals areas of concern. The strongest aspect is profitability, rated at 6/10, while financial strength and valuation are notably weaker, with scores of 3/10 and 2/10, respectively. This indicates that while the company may generate profits, it faces challenges in maintaining robust financial health and an attractive valuation. Investors should weigh these factors carefully when considering the stock.
What Are Insiders Doing with QDEL Stock? Recent insider activity indicates a positive sentiment among QDEL's executives, with insiders purchasing $0.6 million worth of shares in the last three months and no selling reported. This pattern of buying can be interpreted as a sign of confidence in the company's future prospects, potentially signaling that insiders believe the current stock price does not reflect the true value of the business.
However, while insider buying can be a bullish indicator, it is essential to consider the broader market context and the company's financial metrics before making any judgments about the sustainability of such trends.
What This Means for Investors Based on the analysis, QuidelOrtho Corp QDEL appears to be undervalued according to the GF Value™ assessment. However, the company's financial strength and valuation ranks pose potential risks that warrant caution. Investors should remain vigilant and conduct thorough due diligence before considering any positions in QDEL.
For the complete analysis, visit the QuidelOrtho Corp QDEL stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is QDEL's GF Score™?
QDEL has a GF Score™ of 60/100, indicating it is rated above average based on key financial metrics and historical performance.
Is QDEL overvalued or undervalued?
According to the GF Value™, QDEL is currently undervalued, trading at 69.0% below its intrinsic value estimate of $39.69.
What is QDEL's P/E ratio?
QDEL's forward P/E ratio is 5.8x, which is below its 5-year median P/E of 6.6x, suggesting that the stock is trading at a lower valuation compared to its historical averages.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
― LEX Diagnostics Acquisition Expected to Accelerate Growth in Point-of-Care Molecular Diagnostics ―
― Key Product Launches in U.S. and International Markets Expected to Drive Future Growth ―
― Company Updates Full-Year 2026 Financial Guidance ―
, /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the first quarter ended March 29, 2026.
Key First Quarter 2026 Results:
(all comparisons are to the prior year period)
Total revenue was $620 million, as reported Point of Care revenue of $113 million declined by 34% as reported and 35% in constant currency, primarily due to a significantly weaker respiratory season compared to the first quarter of 2025. Labs revenue of $353 million declined by 5% as reported and 8% in constant currency, primarily due to slower distributor sales in China that the Company believes is related to pending changes to the China National Health Security Administration ("NHSA") In Vitro Diagnostics ("IVD") pricing guidelines, business disruption related to the Middle East conflict, and a decrease in revenue related in part to the Company's termination of its joint business arrangement with Grifols. Immunohematology revenue of $138 million grew 8% as reported and 3% in constant currency, primarily driven by growth in North America, China and JPAC. GAAP net loss was $92 million; GAAP operating loss was $32 million; adjusted EBITDA was $109 million. GAAP diluted loss per share was $1.35; adjusted diluted loss per share was $0.04. "Our first quarter results were in line with our preliminary revenue announcement and reflected a significantly weaker respiratory season and business disruption in China and the Middle East," said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho. "Importantly, we believe the underlying business remains strong and we are well positioned to deliver on our objectives to expand our adjusted EBITDA margin and improve cash flow in 2026."
"We completed our acquisition of LEX Diagnostics in April, adding an ultra-fast molecular diagnostics platform for point-of-care testing. We also advanced our key strategic priorities, including the U.S. launch of our High-Sensitivity Troponin assay and the rollout of the VITROS 450 platform in select international markets. We believe these innovations enhance our portfolio and position us to drive sustainable, long-term growth," Blaser continued.
Full-year 2026 Financial Guidance
The Company provided its initial financial guidance for full-year 2026 on February 11, 2026. On April 15, 2026, the Company announced preliminary revenue for the first quarter 2026 and indicated that the low end of its full-year 2026 financial guidance ranges remained achievable. Considering first-quarter performance and current market dynamics in China, the Company has updated its previously provided financial guidance. This guidance includes expected 2026 impact from the current draft of the China NHSA IVD pricing guidelines. The Company cannot fully assess the impact until the final NHSA guidelines and implementation timelines are confirmed. In addition, this guidance does not assume a significant, prolonged impact related to the Middle East conflict.
Full-year 2026 Financial Guidance
Updated (as of 5/5/26)
Previous (as of 2/11/26)
Total revenues (reported)
$2.70 - $2.75 billion
$2.7 - $2.9 billion
Adjusted EBITDA
$615 - $630 million
$630 - $670 million
Adjusted EBITDA margin
23 %
23.3 %
Adjusted diluted earnings per share
$1.80 - $2.00
$2.00 - $2.42
Free cash flow
$100 - $120 million
$120 - $160 million
Please see page 6 of the First Quarter 2026 Financial Results presentation on the "Investor Relations" page of the Company's website for the full list of assumptions on which the Company's current 2026 financial guidance is based.
A reconciliation of forward-looking non-GAAP measures, including adjusted EBITDA, adjusted EBITDA margin, adjusted diluted earnings per share and free cash flow, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. We are not, without unreasonable effort, able to reliably predict the impact of impairment charges and related tax benefits and other non-recurring adjustments. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. In addition, the Company believes any such reconciliation would imply a degree of precision and certainty that could be confusing to investors. See "Forward-Looking Statements" and "Non-GAAP Financial Measures."
Conference Call Information
Following the release of financial results, QuidelOrtho will hold a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho.com. Presentation materials will also be posted to the "Events & Presentations" section of the "Investor Relations" page of the Company's website at the time of the call.
A replay of the conference call will be available shortly after the event on the "Investor Relations" page of the Company's website under the "Events & Presentations" section.
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho's commercial and other strategic goals, financial guidance for 2026 and related assumptions and other future financial condition and operating results, including growth expectations and expected results of operations, financial position or cost-savings and operational improvement initiatives, and other future plans, objectives, strategies, expectations and intentions. Without limiting the foregoing, the words "may," "will," "could," "would," "should," "might," "expect," "anticipate," "believe," "estimate," "plan," "intend," "goal," "project," "strategy," "future," "continue," "aim," "strive," "seek" or similar words, expressions or the negative of such terms or other comparable terminology are intended to identify forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho's management as of the date of this press release and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among others, could cause actual results or outcomes to differ from those set forth or implied in the forward-looking statements: fluctuations in demand for QuidelOrtho's non-respiratory and respiratory products; supply chain, production, logistics, distribution and labor disruptions and challenges; inability to successfully identify, consummate or realize the anticipated benefits of strategic transactions, strategic restructurings, divestitures, spin-offs or discontinuances of certain business operations, or debt financings, on the anticipated timelines, or at all; delays in the development of or failures or delays in the receipt of approvals for new or enhanced products; failure of new products and services to be commercially viable or accepted; changes in reimbursement rates for our products, including reimbursement rate reductions proposed by the China NHSA; disruptions and challenges related to the ongoing conflicts in the Middle East; and other macroeconomic, geopolitical, market, business, competitive and/or regulatory factors affecting the business of QuidelOrtho generally, including those arising from the effects of announced or future or amended tariffs, trade policies, investigations, global trade relations and other tariff-related developments, as well as those discussed in QuidelOrtho's Annual Report on Form 10-K for the fiscal year ended December 28, 2025 and subsequent reports filed with the Securities and Exchange Commission (the "Commission"), including under Part I, Item 1A, "Risk Factors" of the Form 10-K. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date of this press release. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this press release, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.
Non-GAAP Financial Measures
This press release contains financial measures that are considered non-GAAP financial measures under applicable rules and regulations of the Commission, including but not limited to "constant currency Point of Care revenue changes," "constant currency Labs revenue changes," "constant currency Immunohematology revenue changes," "adjusted EBITDA," "adjusted EBITDA margin," "adjusted diluted loss per share," "free cash flow" and other non-GAAP financial measures included in the reconciliation tables accompanying this press release. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These non-GAAP financial measures eliminate impacts of certain non-cash, unusual or other items that the Company does not consider indicative of its ongoing operating performance, and the Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company's historical operating results and comparison to competitors' operating results. The Company's definitions of these non-GAAP measures may differ from similarly titled measures used by others. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company's business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and reports filed with the Commission in their entirety. Reconciliations of the historical non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this press release.
Media Contact:
Stephanie Kleewein
Senior Corporate Communications and PR Manager
[email protected]
QuidelOrtho
Consolidated Statements of Loss
(Unaudited)
(In millions, except per share data)
Three Months Ended
March 29, 2026
March 30, 2025
Total revenues
$ 619.8
$ 692.8
Cost of sales, excluding amortization of intangibles
356.0
349.5
Selling, marketing and administrative
199.3
187.0
Research and development
44.9
53.2
Amortization of intangible assets
46.8
48.0
Restructuring, integration and other charges
4.4
16.1
Other operating expenses
0.2
6.4
Operating (loss) income
(31.8)
32.6
Interest expense, net
51.1
40.0
Other (income) expense, net
(3.4)
1.4
Loss before income taxes
(79.5)
(8.8)
Provision for income taxes
12.3
3.9
Net loss
$ (91.8)
$ (12.7)
Basic loss per share
$ (1.35)
$ (0.19)
Diluted loss per share
$ (1.35)
$ (0.19)
Weighted-average shares outstanding - basic
68.2
67.5
Weighted-average shares outstanding - diluted
68.2
67.5
QuidelOrtho
Condensed Consolidated Balance Sheets
(Unaudited)
(In millions)
March 29, 2026
December 28, 2025
ASSETS
Current assets:
Cash and cash equivalents
$ 140.4
$ 169.8
Accounts receivable, net
359.9
417.0
Inventories
611.5
577.6
Prepaid expenses and other current assets
232.8
250.5
Assets held for sale
32.4
32.4
Total current assets
1,377.0
1,447.3
Property, plant and equipment, net
1,339.3
1,358.3
Right-of-use assets
158.0
155.5
Intangible assets, net
2,520.2
2,563.8
Other assets
234.2
244.4
Total assets
$ 5,628.7
$ 5,769.3
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$ 243.5
$ 279.4
Accrued payroll and related expenses
135.4
120.3
Income tax payable
12.7
11.5
Current portion of borrowings
228.2
178.3
Other current liabilities
342.6
376.6
Total current liabilities
962.4
966.1
Operating lease liabilities
155.4
154.4
Long-term borrowings
2,459.8
2,471.9
Deferred tax liabilities
87.3
90.0
Other liabilities
112.4
166.4
Total liabilities
3,777.3
3,848.8
Total stockholders' equity
1,851.4
1,920.5
Total liabilities and stockholders' equity
$ 5,628.7
$ 5,769.3
QuidelOrtho
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In millions)
Three Months Ended
March 29, 2026
March 30, 2025
Cash (used for) provided by operating activities
$ (33.0)
$ 65.6
Cash used for investing activities
(34.0)
(56.2)
Cash provided by financing activities
37.6
17.6
Effect of exchange rates on cash
—
1.7
Net (decrease) increase in cash, cash equivalents and restricted cash
(29.4)
28.7
Cash, cash equivalents and restricted cash at beginning of period
169.8
98.5
Cash, cash equivalents and restricted cash at end of period
$ 140.4
$ 127.2
Reconciliation to amounts within the consolidated balance sheets:
Cash and cash equivalents
$ 140.4
$ 127.1
Restricted cash in Other assets
—
0.1
Cash, cash equivalents and restricted cash
$ 140.4
$ 127.2
QuidelOrtho
Reconciliation of Non-GAAP Financial Information - Adjusted Net (Loss) Income
(In millions, except per share data; unaudited)
Three Months Ended
March 29, 2026
Diluted EPS
March 30, 2025
Diluted EPS
Net loss
$ (91.8)
$ (1.35)
$ (12.7)
$ (0.19)
Adjustments:
Amortization of intangibles
46.8
48.0
Restructuring, integration and other charges
4.4
16.1
Amortization of deferred cloud computing implementation costs
8.0
4.3
Employee compensation charges
5.5
—
Incremental depreciation on PP&E fair value adjustment
3.3
5.2
Accelerated depreciation
2.0
—
Loss (gain) on investments
0.9
(0.3)
EU medical device regulation transition costs
0.7
0.2
Other adjustments
4.7
1.2
Income tax impact of adjustments
13.1
(11.8)
Adjusted net (loss) income
$ (2.4)
$ (0.04)
$ 50.2
$ 0.74
Weighted-average shares outstanding - diluted
68.2
67.9
QuidelOrtho
Reconciliation of Non-GAAP Financial Information - Adjusted EBITDA
(In millions, unaudited)
Three Months Ended
March 29, 2026
March 30, 2025
Net loss
$ (91.8)
$ (12.7)
Depreciation and amortization
112.9
107.1
Interest expense, net
51.1
40.0
Provision for income taxes
12.3
3.9
Restructuring, integration and other charges
4.4
16.1
Amortization of deferred cloud computing implementation costs
8.0
4.3
Employee compensation charges
5.5
—
Loss (gain) on investments
0.9
(0.3)
EU medical device regulation transition costs
0.7
0.2
Other adjustments
4.7
1.2
Adjusted EBITDA
$ 108.7
$ 159.8
Total revenues
$ 619.8
$ 692.8
Adjusted EBITDA margin
17.5 %
23.1 %
QuidelOrtho
Reconciliation of Non-GAAP Financial Information - Revenues by Business Unit
(In millions, unaudited)
Three Months Ended
March 29, 2026
March 30, 2025
% Change
Currency
Impact
Constant
Currency (a)
Labs
$ 353.1
$ 373.0
(5.3) %
2.3 %
(7.6) %
Immunohematology
138.3
128.5
7.6 %
4.2 %
3.4 %
Donor Screening
7.8
12.8
(39.1) %
0.4 %
(39.5) %
Point of Care
112.8
170.9
(34.0) %
0.6 %
(34.6) %
Molecular Diagnostics
7.8
7.6
2.6 %
4.4 %
(1.8) %
Total revenues
$ 619.8
$ 692.8
(10.5) %
2.1 %
(12.6) %
(a)
The term "constant currency" means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant for each period. This additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP.
QuidelOrtho (QDEL - Free Report) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of $0.37. This compares to earnings of $0.74 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -110.81%. A quarter ago, it was expected that this medical diagnostics company would post earnings of $0.43 per share when it actually produced earnings of $0.46, delivering a surprise of +6.98%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
QuidelOrtho, which belongs to the Zacks Medical - Products industry, posted revenues of $619.8 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.28%. This compares to year-ago revenues of $692.8 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
QuidelOrtho shares have lost about 56.5% since the beginning of the year versus the S&P 500's gain of 5.2%.
What's Next for QuidelOrtho?While QuidelOrtho has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for QuidelOrtho was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #5 (Strong Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.05 on $609.35 million in revenues for the coming quarter and $2.18 on $2.69 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Cresco Labs Inc. (CRLBF - Free Report) , is yet to report results for the quarter ended March 2026.
This company is expected to post quarterly loss of $0.03 per share in its upcoming report, which represents a year-over-year change of +25%. The consensus EPS estimate for the quarter has been revised 30% higher over the last 30 days to the current level.
Cresco Labs Inc.'s revenues are expected to be $148.64 million, down 10.3% from the year-ago quarter.
Key Takeaways QuidelOrtho reported a Q1 adjusted loss of 4 cents per share, missing the consensus estimate.QDEL revenues fell 10.5% year over year as respiratory and Point of Care sales declined sharply.QuidelOrtho maintained 2026 revenue guidance of $2.7B-$2.75B despite margin pressure. QuidelOrtho Corporation (QDEL - Free Report) delivered adjusted loss per share of 4 cents in first-quarter 2026 against earnings per share (EPS) of 74 cents in the prior-year quarter. The figure missed the Zacks Consensus Estimate by 110.8%.
The adjustments include expenses related to the amortization of intangibles, acquisition and integration costs, among others.
GAAP loss per share for the quarter was $1.35 compared with the year-earlier loss of 19 cents.
QDEL’s Revenues in DetailQuidelOrtho registered revenues of $619.8 million in the first quarter of 2026, which decreased 10.5% year over year on a reported basis and 12.6% at constant exchange rate (CER). However, the figure surpassed the Zacks Consensus Estimate by 0.3%.
In the first quarter, Respiratory revenues were $67.9 million (down 43.3% on a reported basis and 43.6% at CER), while Non-Respiratory revenues were $551.9 million (down 3.7% on a reported basis and 6.2% at CER).
Shares of the company lost around 6% in yesterday’s trading session.
QuidelOrtho’s Business Units in DetailQuidelOrtho derives revenues from five business units — Labs, Immunohematology, Donor Screening, Point of Care and Molecular Diagnostics. As a result of the wind-down of the U.S. Donor Screening portfolio, the previously reported Transfusion Medicine business unit is now presented in its two product categories — Immunohematology and Donor Screening.
In the first quarter, Labs revenues were $353.1 million, down 5.3% on a reported basis and 7.6% at CER.
Immunohematologyrevenues were $138.3 million in the first quarter, up 7.6% and 3.4% on a reported basis and at CER, respectively.
Donor Screening revenues were $7.8 million in the first quarter, down 39.1% and 39.5% on a reported basis and at CER, respectively.
Point of Care revenues amounted to $112.8 million in the first quarter, reflecting a decline of 35%on a reported basis and 34.6% at CER.
Molecular Diagnosticsrevenues totaled $7.8million in the first quarter, up 2.6% and down 1.8% on a reported basis and at CER, respectively.
QDEL’s Geographical DistributionGeographically, QuidelOrtho derives revenues from North America, Europe, the Middle East and Africa (EMEA), China, Latin America and Japan and other Asia-Pacific markets (JPAC).
Revenues from North Americaamounted to $328.9million, reflecting a decline of 19.1% on a reported basis and 18.9% at CER.
EMEA revenues amounted to $92.5million, reflecting an increase of 4% on a reported basis and a decline of 6.1% at CER.
Revenues from China amounted to $63.5million, reflecting a decrease of 15.3% on a reported basis and 19% at CER.
Revenues from JPACamounted to $70million, reflecting an uptick of 2.8% on a reported basis and 4.7% at CER.
Revenues from Latin America amounted to $64.9million, reflecting an uptick of 20% on a reported basis and 9.3% at CER.
QuidelOrtho’s Margin TrendIn the quarter under review, QuidelOrtho’s adjusted gross profit declined 21.8% year over year to $271.2 million. The adjusted gross margin contracted 630 basis points (bps) to 43.8%.
Adjusted selling, marketing and administrative expenses increased 2.6% year over year to $184.8 million. Adjusted research and development expenses declined 19.2% year over year to $42.6 million. Adjusted operating expenses of $227.4 million decreased 2.4% year over year.
Adjusted operating profit totaled $43.6 million, reflecting an 59.5% decline from the prior-year quarter’s level. Adjusted operating margin in the first quarter contracted 850 bps to 7%.
QDEL’s Financial PositionQuidelOrtho exited the first quarter of 2026 with cash and cash equivalents of $140.4 million compared with $169.8 million at the end of the fourth quarter of 2025. Total debt (including short-term debt) at the end of first-quarter 2026 was $2.69 billion compared with $2.65 billion at the end of the fourth quarter 2025.
Net cash used by operating activities at the end of the first quarter was $33 million, against net cash provided by operating activities of $65.6 million a year ago.
QuidelOrtho’s 2026 GuidanceQuidelOrtho has provided its financial outlook for 2026.
Total revenues are expected to lie in the range of$2.7-$2.75 billion. The Zacks Consensus Estimate is pegged at $2.69 billion.
Adjusted EPS is expected to be between $1.80 and $2.00. The Zacks Consensus Estimate is pegged at $2.18 per share.
Our TakeQuidelOrtho ended the first quarter of 2026 with mixed results, where revenues surpassed the Zacks Consensus Estimate, but earnings missed significantly. The company continued to witness strength in its Labs and Immunohematology business units, while solid growth across Latin America and resilient performance in EMEA and JPAC were encouraging.
However, persistent weakness in respiratory testing continued to weigh heavily on the top line, with Point of Care and Donor Screening businesses also posting sharp declines. The company’s bottom line deteriorated year over year, while gross and operating margins contracted significantly due to lower volumes and an unfavorable business mix. Additionally, operating cash outflow and elevated debt levels remain concerns despite management maintaining its 2026 revenue outlook.
QDEL’s Zacks Rank and Key PicksQDEL currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks from the broader medical space that are expected to report earnings soon are DexCom, Inc. (DXCM - Free Report) , Encompass Health Corporation (EHC - Free Report) and The Cooper Companies, Inc. (COO - Free Report) .
The Zacks Consensus Estimate for DexCom’s first-quarter 2026 adjusted EPS is currently pegged at 47 cents. The consensus estimate for revenues is pegged at $1.18 billion. DXCM currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DexCom has an estimated long-term growth rate of 20.6%. DXCM’s earnings yield of 4.1% compares favorably with the industry’s negative yield.
Encompass Health currently has a Zacks Rank #2. The Zacks Consensus Estimate for its first-quarter 2026 adjusted EPS is currently pegged at $1.51. The same for revenues is pegged at $1.57 billion.
Encompass Health has an estimated long-term growth rate of 8.8%. EHC’s earnings yield of 5.9% compares favorably with the industry’s 5.6%.
Cooper Companies currently carries a Zacks Rank #2. The Zacks Consensus Estimate for its second-quarter fiscal 2026 adjusted EPS is currently pegged at $1.10. The same for its revenues is pegged at $1.05 billion.
Cooper Companies has an estimated long-term growth rate of 8.4%. COO’s earnings yield of 7.2% compares favorably with the industry’s 6.1%.
The World Health Organization’s recent report of a Hantavirus cluster aboard a cruise ship departing Argentina has refocused global market attention on zoonotic respiratory pathogens.
Three confirmed fatalities and a widening caseload linked to the South Atlantic itinerary have forced an urgent global response to intercept a pathogen characterized by high lethality and rapid pulmonary onset.
Unlike previous isolated incidents, the current multi-country reach of the outbreak has triggered a shift in capital allocation toward biotech and healthcare stocks.
Here are three names that stand to particularly benefit from renewed demand for outbreak‑driven vaccine development, diagnostics, and protective‑equipment supply chains.
Moderna shares are the clearest first‑order beneficiary of renewed Hantavirus fears.
The biotech already has an early‑stage Hantavirus program in collaboration with USAMRIID and Korea University, giving it a head start if governments accelerate funding for high‑risk pathogen vaccines.
The recent Hantavirus outbreak reinforces the value of Moderna’s modular mRNA platform, which can be rapidly adapted to emerging threats.
With capital flowing into rapid‑response vaccine names, MRNA stock stands out as the most direct way to play the biosecurity bid.
At the time of writing, the Street-high price objective on Moderna currently sits at $135, indicating the stock could shoot up over 150% from current levels as the year unfolds.
QuidelOrtho stock could benefit as the Hantavirus outbreak lifts demand for rapid, high-sensitivity respiratory diagnostics.
The firm’s molecular and antigen testing platforms are already popular among hospitals and public health networks – giving it immediate leverage as authorities expand surveillance for Hantavirus-like symptoms.
Any move by governments to broaden screening protocols would directly lift test‑kit volumes and instrument utilization, potentially helping QDEL shares to recover sharply in 2026.
In short, with investors rotating into outbreak-sensitive diagnostics, QuidelOrtho offers one of the cleanest ways to play the surge in global pathogen-detection spending.
The Street-high price target of $38 suggests it could nearly triple from here over the next 12 months.
3M stock also emerges as a major beneficiary of the Hantavirus outbreak because it revives global demand for high‑grade protective equipment.
The firm remains one of the world’s dominant suppliers of N95 respirator, filtration materials, and hospital‑grade barrier products – all of which see an immediate increase in volume when respiratory pathogens with high fatality rates surface.
A potential tightening of public health guidance or expansion of occupational safety protocols may accelerate orders from governments and healthcare systems.
With investors loading up on PPE leaders, 3M offers a straightforward defensive play on outbreak-driven demand, with an added benefit of a rather lucrative 2.81% dividend yield as well.
Wall Street currently rates the behemoth at “overweight”, with price targets going as high as $230, indicating potential upside of nearly 60% from current levels.
, /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today that members of its management team will participate in two upcoming investor conferences:
William Blair 46th Annual Growth Stock Conference, Tuesday, June 2, 2026
Members of QuidelOrtho's management team will participate in a presentation at 12:20 p.m. ET / 9:20 a.m. PT.
Jefferies Global Healthcare Conference, Wednesday, June 3, 2026
Members of QuidelOrtho's management team will participate in a fireside chat at 8:10 a.m. ET / 5:10 a.m. PT.
Interested parties can access the live webcast and replay in the "Events & Presentations" section of the "Investor Relations" page of QuidelOrtho's website at https://ir.quidelortho.com/.
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
, /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 58 of its Science Bytes podcast, focusing on hemolytic disease of the fetus and newborn (HDFN) – a serious but often underrecognized condition driven by maternal alloimmunization.
Bethany Weathersby, Founder of the Allo Hope Foundation
QuidelOrtho Science Bytes, Episode # 58 - HDFN Hosted by Michelle Mullens, Global Product Manager of Portfolio Solutions for Transfusion Medicine at QuidelOrtho, the episode features Bethany Weathersby, Founder and Executive Director of the Allo Hope Foundation. Together, they explore how red blood cell antibodies can impact pregnancy, why awareness and care gaps persist, and how timely diagnostics and coordinated care can dramatically improve outcomes for mothers and babies.
Key Insights:
What is HDFN: How maternal alloimmunization leads to red blood cell antibody formation and fetal risk The impact of awareness gaps: Many patients and providers are unfamiliar with alloantibodies, leading to delayed understanding and care Why lab testing matters: Antibody screening and titers directly guide pregnancy management and risk assessment Inconsistencies in care: Outcomes can vary widely depending on provider knowledge, timing of testing and access to specialized care The patient perspective: Connecting diagnostic workflows to real-world outcomes highlights opportunities to improve care HDFN occurs when a pregnant individual develops antibodies against fetal red blood cell antigens, leading to fetal anemia and other serious complications. While advances in screening and treatment have improved outcomes, the episode highlights ongoing inconsistencies in awareness, access to expertise and clinical management – even in well-resourced healthcare settings.
Through a powerful combination of clinical insight and lived experience, the conversation highlights the critical role of laboratory testing as the foundation of prenatal care decisions and the importance of acting quickly on results to prevent severe outcomes.
Listen to the latest episode of the QuidelOrtho Science Bytes podcast on major streaming platforms or at: https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
About the Allo Hope Foundation
The Allo Hope Foundation (AHF) serves families and clinicians globally navigating red cell alloimmunization and hemolytic disease of the fetus and newborn (HDFN). Led by patients with expertise in education, research, and clinical practice under the oversight of a Medical Advisory Board and Patient Advisory Board, AHF believes survival from HDFN should be an expectation and global reality. AHF manages daily patient counsel for thousands of families, facilitates specialty referrals, conducts and publishes disease research and clinical practice guidelines, and raises global awareness through provider education and public health initiatives.
On May 28, 2026, QuidelOrtho Corp QDEL shares rose 6.0% today, bringing the current price to $13.06. Over the past year, the stock has experienced significant volatility, with a 52-week range between $9.92 and $35.58.
GF Value™ verdict: The current price of $13.06 is 64.9% undervalued compared to the GF Value™ estimate of $37.21.GF Score™: With a score of 48/100, QuidelOrtho Corp is considered average in terms of its overall investment quality.Most notable signal: QuidelOrtho has seen no insider transactions in the last three months, indicating a lack of insider confidence or activity. Is QDEL Overvalued or Undervalued? QuidelOrtho Corp's current share price of $13.06 represents a significant discount to the GF Value™ estimate of $37.21, suggesting that the stock is undervalued by approximately 64.9%. This margin of safety could present an interesting opportunity for potential investors; however, caution is advised due to the GF Valuation label indicating a "Possible Value Trap," which suggests that despite the apparent undervaluation, the company's fundamentals may not support a price recovery. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
While the stock appears undervalued based on GF Value™, the company's financial strength score of 3/10 and a negative Altman Z-Score of -0.16 raise questions about the sustainability of this valuation. Investors might find the potential for high returns appealing, but they should remain aware of the associated risks.
How Does QDEL's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 7.2x 6.7x QuidelOrtho's current forward P/E ratio of 7.2x is slightly above its 5-year median P/E of 6.7x, indicating that the stock is trading above its historical valuation multiples. This P/E analysis appears to disagree with the GF Value™ verdict, which suggests that while the stock may be undervalued based on intrinsic value, its current trading multiples reflect a less favorable valuation compared to its historical performance.
What Does QDEL's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns (backtested 2006-2021).
Metric Rating GF Score™ 48 Financial Strength 3/10 Profitability 5/10 Growth 2/10 Valuation 2/10 Momentum 2/10 QuidelOrtho's GF Score™ of 48/100 indicates that the company is in the average range for investment quality. The strongest aspect of QuidelOrtho's score is its profitability ranking of 5/10, suggesting some stability in earnings performance. Conversely, the weakest areas are its growth and valuation ranks, both at 2/10, which indicate challenges in expanding revenue and maintaining a favorable valuation, respectively.
What Are Insiders Doing with QDEL Stock? In the last three months, there have been no insider transactions involving QuidelOrtho Corp stock. This lack of activity might suggest that insiders are not currently confident in the company's prospects or that they are waiting for more favorable conditions before making any moves. Such patterns can often be interpreted as a sign of uncertainty regarding future performance.
What This Means for Investors Based on the GF Value™ analysis, QuidelOrtho Corp appears to be undervalued at its current price of $13.06, with a significant upside potential when compared to the GF Value™ estimate of $37.21. However, the company's financial challenges and lack of insider activity suggest that investors should proceed with caution.
For the complete analysis, visit the QuidelOrtho Corp QDEL stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is QDEL's GF Score™?
QuidelOrtho Corp has a GF Score™ of 48/100, indicating that it is in the average range for investment quality based on various financial metrics.
Is QDEL overvalued or undervalued?
QuidelOrtho is currently undervalued according to GF Value™, which estimates its intrinsic value at $37.21, significantly higher than its current market price of $13.06.
What is QDEL's P/E ratio?
QuidelOrtho has a forward P/E ratio of 7.2x, which is above its historical median P/E of 6.7x, suggesting that the stock is trading at a higher multiple than it has historically. This could indicate a divergence from expected value based on historical performance.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
, /PRNewswire/ -- QuidelOrtho, a global leader in diagnostic innovation, and the Allo Hope Foundation, a nonprofit dedicated to supporting families and clinicians managing maternal alloimmunization, announced a new collaboration focused on improving prenatal care through education, early testing and stronger connections between laboratory providers, clinicians and patients.
Allo Hope Foundation Maternal red blood cell alloimmunization is a serious, often misunderstood condition that can pose significant risks to the child during pregnancy. Red cell antibodies can cross the placenta and destroy fetal and neonatal red blood cells, causing hemolytic disease of the fetus and newborn (HDFN), a temporary but life-threatening condition that requires timely, specialized treatment. Many families struggle to find clear, early and actionable information, creating gaps in care that disproportionately affect underserved populations. This collaboration aims to change that.
Rooted in a shared purpose, QuidelOrtho and Allo Hope will jointly develop resources that elevate patient voices, increase awareness among healthcare providers and help ensure women receive informed, equitable prenatal testing and care from the very beginning.
"At QuidelOrtho, our mission is to advance diagnostics for a healthier future for all," said Bryan Hanson, Executive Vice President, Global Portfolio Management and Marketing, QuidelOrtho. "Through this collaboration with the Allo Hope Foundation, we are activating that mission in a meaningful new way, helping ensure alloimmunized patients receive the early testing, accurate information and compassionate support they deserve. This is the perfect moment to highlight how diagnostics can directly improve maternal health outcomes, especially for those who have historically been underserved."
The collaboration also reinforces a commitment to patient-centered authenticity.
"At Allo Hope, our work begins and ends with the patient experience," said Bethany Weathersby, Founder and Executive Director, Allo Hope Foundation. "Families facing alloimmunization often feel overwhelmed and isolated. By collaborating with QuidelOrtho, we're able to bring together clinical expertise, trusted diagnostics and lived experience to provide education that is both accurate and deeply human. We're excited to broaden awareness and reach more families earlier, with clarity, compassion, and the support needed, to make survival the standard for children with HDFN."
Beginning this summer, QuidelOrtho and the Allo Hope Foundation will release a series of co-produced educational materials designed for both lab technicians and families.
These educational assets will be made available through both organizations' digital channels.
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
About the Allo Hope Foundation
The Allo Hope Foundation (AHF) serves families and clinicians globally navigating red cell alloimmunization and hemolytic disease of the fetus and newborn (HDFN). Led by patients with expertise in education, research, and clinical practice and guided by a multidisciplinary Medical Advisory Board, Patient Advisory Board, and Board of Directors, AHF believes survival from HDFN should be an expectation and global reality. AHF provides daily patient counsel for thousands of families, facilitates specialty referrals, conducts and publishes disease research and clinical practice guidelines, and raises global awareness through provider education and public health initiatives.
Key Takeaways QDEL's respiratory revenue fell 43.3% to $67.9M as influenza-like illness visits declined.QDEL posted a 10.5% revenue decline and an adjusted loss of 4 cents per share in Q1.QuidelOrtho's gross margin fell to 43.8%, while lower testing demand lifted inventories. QuidelOrtho (QDEL - Free Report) is being reminded that respiratory testing can still significantly influence results even after the post-pandemic reset. A milder and shorter U.S. respiratory season weighed heavily on first-quarter 2026 performance, with management attributing the weakness to lower demand rather than market-share losses.
The distinction is important because respiratory testing remains a meaningful profit driver for the company. While testing protocols remained unchanged and management indicated that market share was stable, influenza-like illness visits declined roughly 30% year over year during the quarter. The weaker patient volumes translated directly into lower testing demand across retail and healthcare settings.
As a result, respiratory revenue fell 43.3% year over year to $67.9 million. The decline highlights an important reality for QuidelOrtho: even when competitive positioning remains intact, a shrinking testing market can materially impact financial performance. QDEL currently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Image Source: Zacks Investment Research
The respiratory shortfall weighed on overall results. First-quarter revenue declined 10.5% year over year to $619.8 million, while the company reported an adjusted loss of 4 cents per share against adjusted earnings of 74 cents per share in the prior-year period. Non-respiratory revenue declined a more modest 3.7% to $551.9 million, helping offset some of the weakness but not enough to fully counter the steep drop in respiratory sales.
Profitability also came under pressure. Adjusted gross margin contracted 630 basis points year over year to 43.8%, reflecting a less favorable product mix and a lower contribution from respiratory testing. The margin impact underscores how sensitive QuidelOrtho's earnings profile remains to fluctuations in respiratory demand.
The softer season also affected working capital. Management noted that lower-than-expected respiratory volumes resulted in elevated inventory levels as production plans exceeded realized demand. This inventory build contributed to weaker cash generation, with operating activities using $33 million during the quarter compared with providing $65.6 million in the year-ago period.
The link between respiratory demand, profitability and cash flow remains straightforward. Lower testing volumes reduce operating leverage, pressure margins through unfavorable mix shifts and can leave inventory levels above expectations. While management continues to pursue productivity and procurement initiatives, respiratory seasonality is likely to remain a key driver of near-term performance.
Compared with more diversified diagnostics peers such as Abbott Laboratories (ABT - Free Report) and Thermo Fisher Scientific (TMO - Free Report) , QuidelOrtho remains more exposed to fluctuations in seasonal respiratory testing demand. The broader business mix at these companies helps cushion the impact of weakness in any single testing category.
For investors, the first-quarter results reinforce that stable market share alone cannot offset the effects of a shrinking end market. Until respiratory testing demand normalizes, QuidelOrtho is likely to face periodic revenue volatility, margin pressure and working-capital challenges tied to seasonal demand trends.
QDEL’s Sales & EPS PictureIn 2026, QDEL is expected to experience a 1.8% decline in revenues. On the profitability front, earnings per share are expected to decline 5.2% year over year.
Image Source: Zacks Investment Research
QDEL’s Valuation PictureQDEL currently trades at a price-to-book ratio of 0.49X, well below its median level of 0.70X over the past year and significantly lower than the industry’s 2.04X.
A month has gone by since the last earnings report for QuidelOrtho (QDEL - Free Report) . Shares have added about 24.1% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is QuidelOrtho due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers.
QuidelOrtho Q1 Earnings Miss Estimates, Revenues Down Y/YQuidelOrtho Corporation delivered adjusted loss per share of 4 cents in first-quarter 2026 against earnings per share of 74 cents in the prior-year quarter. The figure missed the Zacks Consensus Estimate by 110.8%.
The adjustments include expenses related to the amortization of intangibles, acquisition and integration costs, among others.
GAAP loss per share for the quarter was $1.35 compared with the year-earlier loss of 19 cents.
QDEL’s Revenues in DetailQuidelOrtho registered revenues of $619.8 million in the first quarter of 2026, which decreased 10.5% year over year on a reported basis and 12.6% at constant exchange rate (CER). However, the figure surpassed the Zacks Consensus Estimate by 0.3%.
In the first quarter, Respiratory revenues were $67.9 million (down 43.3% on a reported basis and 43.6% at CER), while Non-Respiratory revenues were $551.9 million (down 3.7% on a reported basis and 6.2% at CER).
QuidelOrtho’s Business Units in DetailQuidelOrtho derives revenues from five business units — Labs, Immunohematology, Donor Screening, Point of Care and Molecular Diagnostics. As a result of the wind-down of the U.S. Donor Screening portfolio, the previously reported Transfusion Medicine business unit is now presented in its two product categories — Immunohematology and Donor Screening.
In the first quarter, Labs revenues were $353.1 million, down 5.3% on a reported basis and 7.6% at CER.
Immunohematology revenues were $138.3 million in the first quarter, up 7.6% and 3.4% on a reported basis and at CER, respectively.
Donor Screening revenues were $7.8 million in the first quarter, down 39.1% and 39.5% on a reported basis and at CER, respectively.
Point of Care revenues amounted to $112.8 million in the first quarter, reflecting a decline of 35%on a reported basis and 34.6% at CER.
Molecular Diagnostics revenues totaled $7.8million in the first quarter, up 2.6% and down 1.8% on a reported basis and at CER, respectively.
QDEL’s Geographical DistributionGeographically, QuidelOrtho derives revenues from North America, Europe, the Middle East and Africa (EMEA), China, Latin America and Japan and other Asia-Pacific markets (JPAC).
Revenues from North Americaamounted to $328.9million, reflecting a decline of 19.1% on a reported basis and 18.9% at CER.
EMEA revenues amounted to $92.5million, reflecting an increase of 4% on a reported basis and a decline of 6.1% at CER.
Revenues from China amounted to $63.5million, reflecting a decrease of 15.3% on a reported basis and 19% at CER.
Revenues from JPAC amounted to $70million, reflecting an uptick of 2.8% on a reported basis and 4.7% at CER.
Revenues from Latin America amounted to $64.9million, reflecting an uptick of 20% on a reported basis and 9.3% at CER.
QuidelOrtho’s Margin TrendIn the quarter under review, QuidelOrtho’s adjusted gross profit declined 21.8% year over year to $271.2 million. The adjusted gross margin contracted 630 basis points (bps) to 43.8%.
Adjusted selling, marketing and administrative expenses increased 2.6% year over year to $184.8 million. Adjusted research and development expenses declined 19.2% year over year to $42.6 million. Adjusted operating expenses of $227.4 million decreased 2.4% year over year.
Adjusted operating profit totaled $43.6 million, reflecting an 59.5% decline from the prior-year quarter’s level. Adjusted operating margin in the first quarter contracted 850 bps to 7%.
QDEL’s Financial PositionQuidelOrtho exited the first quarter of 2026 with cash and cash equivalents of $140.4 million compared with $169.8 million at the end of the fourth quarter of 2025. Total debt (including short-term debt) at the end of first-quarter 2026 was $2.69 billion compared with $2.65 billion at the end of the fourth quarter 2025.
Net cash used by operating activities at the end of the first quarter was $33 million, against net cash provided by operating activities of $65.6 million a year ago.
QuidelOrtho’s 2026 GuidanceQuidelOrtho has provided its financial outlook for 2026.
Total revenues are expected to lie in the range of$2.7-$2.75 billion. The Zacks Consensus Estimate is pegged at $2.69 billion.
Adjusted earnings per share is expected to be between $1.80 and $2.00. The Zacks Consensus Estimate is pegged at $2.18 per share.
How Have Estimates Been Moving Since Then?It turns out, estimates revision have trended downward during the past month.
The consensus estimate has shifted -20% due to these changes.
VGM ScoresCurrently, QuidelOrtho has a poor Growth Score of F, a grade with the same score on the momentum front. However, the stock was allocated a grade of B on the value side, putting it in the second quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. It's no surprise QuidelOrtho has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.
Performance of an Industry PlayerQuidelOrtho belongs to the Zacks Medical - Products industry. Another stock from the same industry, GE HealthCare Technologies (GEHC - Free Report) , has gained 0.5% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026.
GE HealthCare reported revenues of $5.13 billion in the last reported quarter, representing a year-over-year change of +7.4%. EPS of $0.99 for the same period compares with $1.01 a year ago.
For the current quarter, GE HealthCare is expected to post earnings of $1.04 per share, indicating a change of -1.9% from the year-ago quarter. The Zacks Consensus Estimate has changed -1.9% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #4 (Sell) for GE HealthCare. Also, the stock has a VGM Score of C.
Investors in QuidelOrtho Corporation (QDEL - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 18, 2026 $37.50 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?Clearly, options traders are pricing in a big move for QuidelOrtho shares, but what is the fundamental picture for the company? Currently, QuidelOrtho is a Zacks Rank #5 (Strong Sell) in the Medical – Products industry that ranks in the Bottom 30% of our Zacks Industry Rank. Over the last 60 days, no analysts have increased their earnings estimates for the current quarter, while one analyst has revised the estimate downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from 12 cents per share to 4 cents in that period.
Given the way analysts feel about QuidelOrtho right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
